Background
The pro-survival protein myeloid cell leukaemia 1 (Mcl-1) is overexpressed in many cancers, but the development of small molecules targeting this protein that are amenable for clinical testing has been challenging.
Clinical studies
Servier is collaborating with Novartis for the clinical development of S64315. The candidate is currently being tested in multiple phase 1 studies in patients with acute myeloid leukaemia (AML), myelodysplastic syndrome (MDS), multiple myeloma (MM) and large B-cell diffuse lymphoma (DLBCL).
Vernalis Research is entitled to receive development milestones and royalties on net sales.
« Back to Glossary Index